First Time Loading...

Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276

Watchlist Manager
Jiangsu Hengrui Pharmaceuticals Co Ltd Logo
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Watchlist
Price: 46.16 CNY -0.04% Market Closed
Updated: May 4, 2024
Section:
 

Relative Value

The Relative Value of one Jiangsu Hengrui Pharmaceuticals Co Ltd stock under the Base Case scenario is 29.83 CNY. Compared to the current market price of 46.16 CNY, Jiangsu Hengrui Pharmaceuticals Co Ltd is Overvalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
29.83 CNY
Overvaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

13.1
P/S
P/S
Price to Sales
13.1
vs History
53
vs Industry
13
Median 3Y
12.2
Median 5Y
13.7
Industry
2.4
Forward
12.4
More Details
69.8
P/E
P/E
Price to Earnings
69.8
vs History
50
vs Industry
5
Median 3Y
67.9
Median 5Y
69.8
Industry
22.9
Forward
63
More Details
86.7
P/OCF
P/OCF
Price to OCF
86.7
vs History
61
vs Industry
4
Median 3Y
87.5
Median 5Y
91
Industry
17.1
More Details
186.4
P/FCFE
P/FCFE
Price to FCFE
186.4
vs History
36
vs Industry
4
Median 3Y
188.1
Median 5Y
150.1
Industry
23.2
More Details
7.6
P/B
P/B
Price to Book Value
7.6
vs History
61
vs Industry
9
Median 3Y
7.4
Median 5Y
9.2
Industry
2.1
More Details
12.4
EV/S
EV/S
Enterprise Value to Sales
12.4
vs History
53
vs Industry
13
Median 3Y
11.4
Median 5Y
12.9
Industry
2.6
Forward
11.7
More Details
14.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.8
vs History
53
vs Industry
13
Median 3Y
13.7
Median 5Y
15.5
Industry
5.1
More Details
76.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
76.7
vs History
26
vs Industry
4
Median 3Y
71.9
Median 5Y
71.4
Industry
13.6
Forward
54.3
More Details
76.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
76.7
vs History
26
vs Industry
4
Median 3Y
71.9
Median 5Y
71.4
Industry
17
Forward
62.9
More Details
81.8
EV/OCF
EV/OCF
Enterprise Value to OCF
81.8
vs History
66
vs Industry
5
Median 3Y
82.6
Median 5Y
87.4
Industry
15.8
More Details
177.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
177.7
vs History
31
vs Industry
4
Median 3Y
175.7
Median 5Y
137.7
Industry
17.6
More Details
11.7
EV/IC
EV/IC
Enterprise Value to IC
11.7
vs History
66
vs Industry
10
Median 3Y
11.7
Median 5Y
15.2
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Jiangsu Hengrui Pharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
293.5B CNY 13.1 69.8 76.7 76.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
697.9B USD 20.4 133.2 60.2 69.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.2 33 36
US
Johnson & Johnson
NYSE:JNJ
357.8B USD 4.4 8.8 11.8 15.5
US
Merck & Co Inc
NYSE:MRK
323.8B USD 5.3 140.4 33.4 53
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.4 140.7 225.6
CH
Novartis AG
SIX:NOVN
179.8B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
173.2B CHF 3 15.1 8.6 10.2
US
Pfizer Inc
NYSE:PFE
155.7B USD 2.7 73.5 11 16.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.